Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
